A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

Phase 1

Recruiting

• Conditions: Healthy
• Interventions: Drug: LY4292009; Drug: Placebo

• Registration Number: NCT06977880
• Lead Sponsor: Morphic Holdings, Inc, a wholly owned subsidiary of Eli Lilly and Company

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-02-19
• Status Verified: 2025-05
• Study First Submitted: 2025-05-12
• Study First Submitted QC: 2025-05-12
• Last Update Submitted: 2025-05-12
• Study First Posted: 2025-05-18
• Last Update Posted: 2025-05-18
• Primary Completion: 2026-01
• Study Completion: 2026-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Body mass index (BMI) within 18.0 kg/m² to 30.0 kg/m², inclusive

• If male, meets one of the following:

  • can procreate and agree to use one of the accepted to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration.
  • is unable to procreate; defined as surgically sterile (i.e., has undergone a vasectomy at least 180 days prior to the first study drug administration)

• if female, meets one of the following:

  • is of childbearing potential and agrees to use an acceptable contraceptive method.

  • is of non-childbearing potential, defined as either:

    • Surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or

  • is in a postmenopausal state:

    • At least 1 year without menses and without an alternative medical condition prior to the screening, and follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at screening or at least 1 year without menses and without an alternative medical condition prior to the screening, follicle stimulating hormone FSH levels < 40 milli-international units per milliliter (mIU/mL) and estradiol serum level ≤150 picomole/Liter (pmol/L) at screening

Exclusion Criteria

• Female who is lactating or who is pregnant according to the pregnancy test at screening or prior to the first study drug administration, or planning to become pregnant during the study period up to 30 days after the last study drug administration
• Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum, chewing tobacco, electronic cigarettes) within 1 month before screening and/or inability to refrain from nicotine from screening until the end of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort A1	LY4292009	Participants received LY4292009 orally.
Cohort A2	LY4292009	Participants received LY4292009 orally.
Cohort A3	LY4292009	Participants received LY4292009 orally.
Cohort A4	LY4292009	Participants received LY4292009 orally.
Cohort A5	LY4292009	Participants received LY4292009 orally.
Cohort A6 (Optional)	LY4292009	Participants received LY4292009 orally.
Cohort B1	LY4292009	Participants received LY4292009 orally.
Cohort B2	LY4292009	Participants received LY4292009 orally.
Cohort B3	LY4292009	Participants received LY4292009 orally.
Cohort B4 (Optional)	LY4292009	Participants received LY4292009 orally.
Placebo	Placebo	Participants receive placebo.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Laboratory Parameter and Vital Signs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	Baseline to Study Completion (Up to Day 7)
Number of Participants with Clinically Significant Changes in Cardiovascular Evaluation in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	Baseline to Study Completion (Up to Day 7)
Number of Participants with One or More Serious Adverse Event(s) (SAEs) in (Cohort A1-A6) and MAD (Cohort B1-B4)	Baseline to Study Completion (Up to Day 7)
Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	Baseline to Study Completion (Up to Day 17)
Percentage of Participants with TEAEs and SAEs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	Baseline to Study Completion (Up to Day 7)

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Maximum Concentration (Cmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Maximum observed plasma concentration
PK: Time to Maximum Concentration (Tmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Time to reach Cmax, defined as the first point if multiple maximum values occur.
PK: Area Under the Concentration Curve (AUC) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose
PK: Time to Half Life (T1/2) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Apparent first-order terminal phase half-life, calculated as 0.693/λ
PK: AUC From Time Zero to Infinity (AUC 0-inf) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Area under the concentration-time curve from time 0 extrapolated to infinity. Calculated as the sum of AUC0-t plus the ratio of the last measurable concentration to the terminal phase rate constant (λz).
PK: CL/F in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Apparent total clearance after oral administration, calculated as Dose/AUC0-inf
PK: Vd/F in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Apparent volume of distribution during terminal phase after oral administration, calculated as Dose/\[λz\*AUC0-inf\]
PK: Urine: Ae(total) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	otal amount of urinary excretion (cohorts participating in urinary PK sample collection only)
PK: CLR in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)	SAD Cohorts: Predose up to Day 4 Postdose	Clearance of urinary excretion (cohorts participating in urinary PK sample collection only), calculated as Ae/AUC0-inf

Trial Locations

Locations (1)

Altasciences Company Inc.; 🇨🇦 Mont-royal, Quebec, Canada